Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BioVie Inc. (BIVI)

2.7892   -0.001 (-0.03%) 09-21 10:43
Open: 2.79 Pre. Close: 2.79
High: 2.9099 Low: 2.76
Volume: 31,231 Market Cap: 103(M)

Technical analysis

as of: 2023-09-21 10:14:48 AM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 4.19     One year: 4.8
Support: Support1: 2.76    Support2: 2.29
Resistance: Resistance1: 3.59    Resistance2: 4.1
Pivot: 3.21
Moving Average: MA(5): 2.99     MA(20): 3.25
MA(100): 5     MA(250): 5.64
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 0.6     %D(3): 8.4
RSI: RSI(14): 28.5
52-week: High: 14.38  Low: 1.96
Average Vol(K): 3-Month: 214 (K)  10-Days: 261 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIVI ] has closed above bottom band by 4.5%. Bollinger Bands are 32.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.07 - 3.1 3.1 - 3.11
Low: 2.72 - 2.75 2.75 - 2.77
Close: 2.75 - 2.79 2.79 - 2.82

Company Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Headline News

Tue, 19 Sep 2023
2023-09-19 | NDAQ:BIVI | Press Release | BioVie Inc - Stockhouse Publishing

Mon, 11 Sep 2023
Is BioVie Inc (BIVI) a Stock to Watch After Gaining 22.65% This Week? - InvestorsObserver

Wed, 30 Aug 2023
Although BioVie Inc. (NASDAQ:BIVI) insiders have sold lately, they have the highest ownership with 64% stake - Yahoo Finance

Mon, 28 Aug 2023
BioVie Presents Data for NE3107 at 2023 International Congress of ... - GlobeNewswire

Fri, 11 Aug 2023
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV - Yahoo Finance

Tue, 18 Jul 2023
BioVie Issues Letter to Shareholders - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 37 (M)
Shares Float 13 (M)
% Held by Insiders 65.1 (%)
% Held by Institutions 5.8 (%)
Shares Short 1,240 (K)
Shares Short P.Month 999 (K)

Stock Financials

EPS -1.47
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.41
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -102.1
Return on Equity (ttm) -528.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.22
Qtrly Earnings Growth 0
Operating Cash Flow -40 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -1.9
PEG Ratio 0
Price to Book value 6.57
Price to Sales 0
Price to Cash Flow -2.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.